Latest From Exelixis Inc.
New top-line results from Japanese study set stage for submission of esaxerenone in additional high-need indication.
Full data at ESMO show Opdivo managed to scrape a tolerability edge over standard-of-care sorafenib in liver cancer, but eyes were drawn to Roche’s early study of Tecentriq/Avastin as the way forward in this difficult-to-treat cancer.
Q1 2019 saw a jump in merger and acquisition activity. Informa’s Biomedtracker has cast an analytical eye on three of the major deals, namely buys by Roche, Lilly and BMS.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Exelixis Inc.
- Senior Management
Michael M Morrissey, PhD, Pres. & CEO
Christopher J Senner, EVP, CFO
Peter Lamb, PhD, EVP, Scientific Strategy & CSO
Gisela M Schwab, MD, Pres., Prod. Dev. & CMO
Dana T Aftab, PhD, EVP, Bus. Operations
- Contact Info
Phone: (650) 837-7000
1851 Harbor Bay Parkway
Alameda, CA 94502
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.